The structure of the dopamine D 3 receptor bound to cariprazine reveals principles for partial agonists with designed pharmacology

Структура дофаминового рецептора D3 в комплексе с карипразином раскрывает принципы создания частичных агонистов с заданными фармакологическими свойствами
J. Robert Lane, György M. Keserű, Meritxell Canals, Moran Shalev-Benami, Caleb D. Vogt, Michel Bouvier, Amy Hauck Newman, Attila Egyed, Dóra Kiss, Supriya A. Gaitonde, Eliane Yardeni, Julie Sanchez, Keshet Shavit, Dénes Szepesi Kovács, Jacqueline Glenn
2026-08-28

bitopic ligandscariprazinecryo-electron microscopydopamine D3 receptorpartial agonists
The third-generation antipsychotic cariprazine is a low-efficacy partial agonist of the dopamine D 3 receptor (D 3 R). Here, we report the cryo–electron microscopy structure of cariprazine bound to D 3 R, establishing a framework for understanding ligand recognition in this receptor. We further determine structures of D 3 R in complex with a series of cariprazine derivatives spanning inverse agonists to high-efficacy partial agonists. Integration of structural data with pharmacological profiling and molecular dynamics simulations reveals how subtle chemical modifications translate into distinct functional outcomes. Determinants distinguishing agonism from inverse agonism are well defined, whereas differences among partial agonists arise from small positional shifts of the ligand within the orthosteric binding site. In contrast, the extended binding site primarily modulates ligand stability, affinity, and receptor selectivity. These findings establish a mechanistic link between bitopic ligand architecture and receptor activation, providing a “ligand-centric” view of D 3 R signaling. Leveraging these principles, we designed and validated cariprazine derivatives with enhanced D 3 /D 2 selectivity and partial agonist activity. Together, this work provides a structural and pharmacological blueprint for the rational design of D 3 R-targeting ligands with tailored efficacy and therapeutic profiles.
1
Agonism versus inverse agonism is determined by well-defined structural features, whereas partial-agonist efficacy differences arise from small ligand positional shifts in the orthosteric site.
2
Structure-guided design produced cariprazine derivatives with enhanced D3/D2 selectivity and partial-agonist activity, supporting rational tailoring of therapeutic profiles.
3
Structures of cariprazine derivatives spanning inverse agonists to high-efficacy partial agonists reveal how subtle chemical changes produce distinct functional outcomes.
4
The cryo-EM structure of cariprazine-bound dopamine D3 receptor establishes a framework for understanding ligand recognition.
5
The extended binding site primarily controls ligand stability, affinity, and receptor selectivity rather than directly determining partial-agonist efficacy.

Dopamine D3 receptor (D3R) bound to cariprazine and its derivatives

Structural and pharmacological determinants of ligand recognition, receptor activation, efficacy, affinity, stability, and selectivity, including how bitopic ligand modifications tune D3R signaling and therapeutic profiles

Publication Details
Publication Date
2026-08-28
Journal
Publisher
ISSN
Cited by
0
Access Type
Author Information
Authors
J. Robert Lane
György M. Keserű
Meritxell Canals
Moran Shalev-Benami
Caleb D. Vogt
Michel Bouvier
Amy Hauck Newman
Attila Egyed
Dóra Kiss
Supriya A. Gaitonde
Eliane Yardeni
Julie Sanchez
Keshet Shavit
Dénes Szepesi Kovács
Jacqueline Glenn
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%